




DOCKET NO.: 268949US0X PCT



COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

ATTORNEYS AT LAW

RE: Application Serial No.: 10/530,056

Applicants: Yasutoshi KOGA et al

Filing Date: April 4, 2005

For: COMPOSITION FOR PREVENTING/ TREATING
THE EXPRESSION OF CLINICAL SYMPTOM IN
DISEASE CAUSED BY MITOCHONDRIAL
DYSFUNCTION

Group Art Unit: 1645

STEPHEN G. BAXTER
(703) 413-3000
SBAXTER@OBLON.COM

SIR:

Attached hereto for filing are the following papers:

INFORMATION DISCLOSURE STATEMENT; SUPPLEMENTARY PARTIAL EUROPEAN
SEARCH REPORT; FORM PTO-1449; CITED REFERENCES (5)

Our check in the amount of -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Stephen G. Baxter
Registration No. 32,884

James J. Kelly
Registration No. 41,504

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Yasutoshi KOGA et al

SERIAL NO.: 10/530,056

GROUP ART UNIT: 1645

FILED: April 4, 2005

FOR: COMPOSITION FOR PREVENTING/ TREATING THE EXPRESSION OF
CLINICAL SYMPTOM IN DISEASE CAUSED BY MITOCHONDRIAL DYSFUNCTIONINFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicants wish to disclose the following information.

REFERENCES

The Applicants wish to make of record the references listed on the attached Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

RELATED CASES

Attached is a list of Applicants pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 C.F.R. §1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached Form PTO-1449.

A check or credit card payment form is attached in the amount required under 37 C.F.R. §1.17(p).

CERTIFICATION


Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement.


DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Stephen G. Baxter
Registration No. 32,884



James J. Kelly
Registration No. 41,504

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 268949US0X PCT		SERIAL NO. 10/530,056	
LIST OF REFERENCES CITED BY APPLICANT <i>APR 04 2006</i>		APPLICANT		Yasutoshi KOGA et al			
		FILING DATE		GROUP 1645			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	TRADE DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA							
AB							
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION		
					YES	NO	
AO	197 05 233	08/13/98	GERMANY				XXX
AP							
AQ							
AR							
AS							
AT							
AU							
AV							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
AW	Y. KOGA et al, "Effects of L-arginine on the acute phase of strokes in three patients with MELAS", <u>NEUROLOGY</u> , March 12, 2002, Vol. 58, No. 5, pp. 827-828, XP-002361397.						
AX	Y. KOGA et al, "Endothelial dysfunction in patients with MELAS: role of oxidative stress to stroke", <u>AMERICAN JOURNAL OF HUMAN GENETICS</u> , October 2001, Vol. 69, No. 4, pg. 680, XP-002361398.						
AY	S. BODE-BÖGER et al, "L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship", <u>BRITISH JOURNAL OF CLINICAL PHARMACOLOGY</u> , November 1998, Vol. 46, No. 5, pp. 489-497, XP-002361747.						
AZ	L. ROBBINS, "Post-traumatic headache with scintillating scotoma treated with phenytoin (dilantin)", <u>HEADACHE 1989 UNITED STATES</u> , 1989, Vol. 29, No. 8, pp. 515-516, XP-002361526.						
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							